var data={"title":"Ofloxacin (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ofloxacin (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390296?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ofloxacin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ofloxacin (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=ofloxacin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ofloxacin (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496286\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Tendonitis and tendon rupture:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones, including ofloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients (usually older than 60 years), patients taking corticosteroid drugs, and patients with kidney, heart, or lung transplants.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Myasthenia gravis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid ofloxacin in patients with a known history of myasthenia gravis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496295\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Oflox;</li>\n      <li>Novo-Ofloxacin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9498132\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Fluoroquinolone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497845\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervicitis/urethritis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nongonococcal (due to Chlamydia trachomatis):</i> 300 mg every 12 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Gonococcal (acute, uncomplicated):</i> 400 mg as a single dose; <b>Note:</b> As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of uncomplicated gonococcal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic bronchitis (acute exacerbation), community-acquired pneumonia, skin and skin structure infections (uncomplicated):</b> Oral: 400 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease (acute):</b> Manufacturer's labeling: 400 mg every 12 hours for 10 to 14 days. <b>Note:</b> The CDC recommends use only if standard cephalosporin therapy is not feasible (patients with severe cephalosporin allergy) and community prevalence of quinolone-resistant gonococcal organisms is low. CDC recommends use in combination with metronidazole. Follow-up and culture and sensitivity must be confirmed (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostatitis:</b> Oral: 300 mg every 12 hours for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>UTI:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Uncomplicated:</i> 200 mg every 12 hours for 3 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Complicated:</i> 200 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epididymitis (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Likely caused by enteric organisms:</i> 300 mg twice daily for 10 days (CDC [Workowski 2015]) or 200 mg twice daily for 14 days (Canadian STI Guidelines 2008 [Update 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Likely caused by sexually transmitted chlamydia and gonorrhea and enteric organisms in men who practice insertive anal sex:</i> 300 mg once daily for 10 days in combination with ceftriaxone (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leprosy (multibacillary) (off-label use):</b> Oral: 400 mg once daily (in combination with dapsone and rifampin) for 12 months (WHO 2012) <b>or</b> alternatively, 400 mg once monthly (in combination with monthly rifampin and minocycline) for 24 months (Villahermosa 2004; WHO 1998; WHO 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leprosy (paucibacillary) (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Multiple-dose regimen:</i> 400 mg once daily (in combination with rifampin) for 4 weeks (Balagon 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Single-dose regimen:</i> 400 mg as a single dose (in combination with single doses of rifampin and minocycline) (Manickam 2012). <b>Note:</b> Found to be less effective than standard WHO multiple drug therapy (WHO-MDT) for paucibacillary leprosy; should only be used if close follow-up of relapse is possible (Manickam 2012; Setia 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spontaneous bacterial peritonitis (off-label use):</b> Oral: 400 mg twice daily (AASLD [Runyon 2012]; Navasa 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler's diarrhea (off-label use):</b> Oral: 200 mg twice daily for 1 to 3 days (IDSA [Hill 2006]) <b>or</b> 400 mg once daily as a single dose or for 3 days, with or without loperamide (ACG [Riddle 2016]). If symptoms not resolved after 24 hours, continue with a 3-day therapy course. A 3-day course of therapy is recommended in patients with fever or dysentery; enteric infection due to <i>Shigella dysenteriae</i> is an exception and a 5-day treatment duration is superior to single dose or 3-day regimens (ACG [Riddle 2016]). <b>Note:</b> Fluoroquinolone resistance is increasing; azithromycin may be preferred, particularly in regions such as southeast Asia or India with a high prevalence of <i>Campylobacter</i> (ACG [Riddle 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497846\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497847\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adults: Oral: After a normal initial dose, adjust as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl 20 to 50 mL/minute: Administer usual recommended dose every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &lt;20 mL/minute: Administer half the usual recommended dose every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent hemodialysis (IHD): 100 to 200 mg after dialysis (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis: 200 mg every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous renal replacement therapy (CRRT): 300 mg every 24 hours (Aronoff 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497848\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (eg, cirrhosis with or without ascites): Maximum dose: 400 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497986\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg [DSC], 300 mg, 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496347\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496293\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088599.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlmzuJ2+fbdxZtYfgShrzKFg==&amp;TOPIC_ID=9892\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088599.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497866\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Administer with or without food. Do not take within 2 hours of sucralfate, didanosine, iron, zinc, or antacids containing magnesium, calcium, or aluminum. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496348\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of acute exacerbations of chronic bronchitis, community-acquired pneumonia, skin and skin structure infections (uncomplicated), urethral and cervical gonorrhea (acute, uncomplicated), urethritis and cervicitis (nongonococcal) due to <i>Chlamydia trachomatis</i> infection, mixed infections of the urethra and cervix, pelvic inflammatory disease (acute), cystitis (uncomplicated), urinary tract infections (complicated), prostatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of gonococcal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730957\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Epididymitis; Leprosy (multibacillary); Leprosy (paucibacillary); Spontaneous bacterial peritonitis (treatment); Traveler's diarrhea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497559\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (1% to 9%), insomnia (3% to 7%), dizziness (1% to 5%), fatigue (1% to 3%), drowsiness (1% to 3%), sleep disorder (1% to 3%), nervousness (1% to 3%), pain (trunk)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (&le;3%), skin rash (&le;3%), genital pruritus (women: 1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3% to 10%), diarrhea (1% to 4%), vomiting (1% to 4%), abdominal cramps (1% to 3%), constipation (1% to 3%), decreased appetite (1% to 3%), dysgeusia (1% to 3%), flatulence (1% to 3%), gastrointestinal distress (1% to 3%), xerostomia (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginitis (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal dreams, anaphylaxis, anxiety, auditory disturbance (decreased acuity), blurred vision, chills, cognitive dysfunction, cough, depression, ecchymosis, edema, erythema nodosum, euphoria, exacerbation of myasthenia gravis, Gilles de la Tourette's syndrome, hallucination, hepatic insufficiency, hepatic failure, hepatitis, hepatotoxicity (idiosyncratic; Chalasani 2014), hyperglycemia, hypoglycemia, hypertension, increased intracranial pressure, increased thirst, interstitial nephritis, limb pain, malaise, palpitations, paresthesia, peripheral neuropathy, photophobia, pneumonitis, pseudotumor cerebri, psychotic reaction, rhabdomyolysis, rupture of tendon, seizure, skin photosensitivity, Stevens-Johnson syndrome, syncope, tendonitis, tinnitus, torsades de pointes, toxic epidermal necrolysis, vasculitis, vasodilatation, vertigo, weakness, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497548\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ofloxacin, other quinolones, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497549\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Altered cardiac conduction: Fluoroquinolones may prolong QTc interval; avoid use in patients with a history of QTc prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: Tremor, restlessness, confusion, and very rarely hallucinations, increased intracranial pressure (including pseudotumor cerebri) or seizures may occur; use with caution in patients with known or suspected CNS disorder. Discontinue in patients who experience significant CNS adverse effects (eg, dizziness, hallucinations, suicidal ideations or actions).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as s systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Severe, sometimes fatal,  hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral neuropathy: Peripheral neuropathy has been reported (rare); may occur soon after initiation of therapy and may be irreversible; discontinue if symptoms of sensory or sensorimotor neuropathy occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate to severe phototoxicity reactions. Discontinue use if photosensitivity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tendon inflammation/rupture: <b>[US Boxed Warning]: There have been reports of tendon inflammation and/or rupture with quinolone antibiotics; risk may be increased with concurrent corticosteroids, organ transplant recipients, and in patients &gt;60 years of age.</b> Rupture of the Achilles tendon sometimes requiring surgical repair has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps) have also been reported. Strenuous physical activity may be an independent risk factor for tendonitis. Discontinue at first sign of tendon inflammation or pain. May occur even after discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: <b>[US Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis.</b> Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported; avoid use in patients with myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Use with caution in individuals at risk of seizures (CNS disorders or concurrent therapy with medications which may lower seizure threshold). Potential for seizures, although very rare, may be increased with concomitant NSAID therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Syphilis: Since ofloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later. <b>Note:</b> As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of uncomplicated gonococcal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Adverse effects (eg, tendon rupture, QT changes) may be increased in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497653\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497654\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9892&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Quinolones may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents.<b> Exceptions: </b>Calcium Chloride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid.  Management: Avoid concomitant use of delamanid and quinolone antibiotics if possible. If coadministration is considered to be unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heroin: Quinolones may enhance the adverse/toxic effect of Heroin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Quinolones. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the absorption of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after sevelamer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Quinolones may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents. <b> Exceptions: </b>Dyphylline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Quinolones may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496354\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9496355\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Ofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid. Serum concentrations of ofloxacin may be lower during pregnancy than in nonpregnant patients (Giamarellou 1989). Based on available data, an increased risk of teratogenic effects has not been observed following ofloxacin use during pregnancy (Padberg 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497547\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ofloxacin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15577087\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor CBC, renal and hepatic function periodically if therapy is prolonged.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497678\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ofloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; bactericidal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497680\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed into body tissues and fluids, including blister fluid, cervix, lung, ovary, prostatic tissue, skin, and sputum ; V<sub>d</sub>: 2.4 to 3.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 20% to 32%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 98%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~9 hours (biphasic: 4 to 5 hours [6.4 to 7.4 hours in elderly patients] and 20 to 25 hours [accounts for &lt;5%]); prolonged with renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine: 65% to 80% (as unchanged drug); feces: 4%  to 8%; &lt;10% is metabolized</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9497988\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ofloxacin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (50): $737.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $1,788.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961995\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Akilen (ID, SG);</li>\n      <li>Avaflox (LK);</li>\n      <li>Biloxcin (VN);</li>\n      <li>Cilox (ZW);</li>\n      <li>Danoflox (ID);</li>\n      <li>Evaflox (MY);</li>\n      <li>Flobacin (IT);</li>\n      <li>Flogirax (BR);</li>\n      <li>Floksan (UA);</li>\n      <li>Flotavid (ID);</li>\n      <li>Flovid (HK, PH, SG);</li>\n      <li>Floxil (AR);</li>\n      <li>Floxitop (EC);</li>\n      <li>Floxstat (BB, BM, BS, CO, EC, GY, JM, NL, PR, SR, TT, VE);</li>\n      <li>Fugacin (VN);</li>\n      <li>Hyflox (TH);</li>\n      <li>Kinflocin (TW);</li>\n      <li>Kinoxacin (KR);</li>\n      <li>Loxinter (ID);</li>\n      <li>Loxwin (VN);</li>\n      <li>Medofloxine (MY);</li>\n      <li>Mefoxa (ID);</li>\n      <li>Menazin (VN);</li>\n      <li>Microbac (EC);</li>\n      <li>Novecin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nufafloqo (ID);</li>\n      <li>Ofaksyn (UA);</li>\n      <li>Ofcin (MY, TH, TW);</li>\n      <li>Ofla (TH);</li>\n      <li>Oflacin (BD);</li>\n      <li>Oflamed (HK);</li>\n      <li>Oflin (IN);</li>\n      <li>Oflobid (LK);</li>\n      <li>Oflocee (TH);</li>\n      <li>Oflocet (FR, NZ, PT);</li>\n      <li>Oflocin (IT);</li>\n      <li>Oflodal (TW);</li>\n      <li>Oflodex (IL);</li>\n      <li>Oflodura (DE);</li>\n      <li>Oflovir (ES);</li>\n      <li>Ofloxin (CZ, EE, LT, RO, SK, TH);</li>\n      <li>Ofloxol (MY);</li>\n      <li>Oltrex (GT);</li>\n      <li>Onexacin (PH);</li>\n      <li>Orivid (TH);</li>\n      <li>Orocin (KR);</li>\n      <li>Oxacid (MT);</li>\n      <li>Oxacin (TW);</li>\n      <li>Pharflox (ID);</li>\n      <li>Quotavil (HK);</li>\n      <li>Rilox (ID);</li>\n      <li>Sinflo (TW);</li>\n      <li>Tabrin (GR);</li>\n      <li>Tafloc (ZA);</li>\n      <li>Taravid (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Tariflox (ID);</li>\n      <li>Tarivid (AT, BE, BF, BJ, CH, CI, CL, DK, EE, ET, FI, GB, GH, GM, GN, HN, ID, IE, IL, IN, JP, KE, KR, LR, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NO, PK, PL, PT, RU, SC, SD, SE, SG, SK, SL, SN, TH, TN, TR, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Taroflex (SK);</li>\n      <li>Telbit (KR);</li>\n      <li>Uro Tarivid (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Vioflox (KR);</li>\n      <li>Vioson (PH);</li>\n      <li>Viotisone (TH);</li>\n      <li>Zanocin (IN, LV, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>, 16th ed, New York, NY: Medical Letter, 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20496567\"></a>Balagon MF, Cellona RV, Abalos RM, Gelber RH, Saunderson PR. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy. <i>Lepr Rev</i>. 2010;81(1):27-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/20496567/pubmed\" target=\"_blank\" id=\"20496567\">20496567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,&rdquo; <i>MMWR Recomm Rep</i>, 2007, 56(14):332-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/17431378/pubmed\" target=\"_blank\" id=\"17431378\">17431378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedrich LV and Dougherty R, &ldquo;Fatal Hypoglycemia Associated With Levofloxacin,&rdquo; <i>Pharmacotherapy</i>, 2004, 24(12):1807-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/15585448/pubmed\" target=\"_blank\" id=\"15585448\">15585448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frothingham R, &ldquo;Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(9):1269-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16206101/pubmed\" target=\"_blank\" id=\"16206101\">16206101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gavin JR 3rd, Kubin R, Choudhri S, et al, &ldquo;Moxifloxacin and Glucose Homeostasis: A Pooled-Analysis of the Evidence From Clinical and Postmarketing Studies,&rdquo; <i>Drug Saf</i>, 2004, 27(9):671-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/15230648/pubmed\" target=\"_blank\" id=\"15230648\">15230648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giamarellou H, Kolokythas E, Petrikkos G, et al. &quot;Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women,&quot; Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida.<i> Am J Med</i>. 1989; 87(5A):49S-51S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/2589353/pubmed\" target=\"_blank\" id=\"2589353\">2589353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graumlich JF, Habis S, Avelino RR, et al, &ldquo;Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(10):1296-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16185172/pubmed\" target=\"_blank\" id=\"16185172\">16185172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill DR, Ericsson CD, Pearson RD, et al; The practice of travel medicine: guidelines by the Infectious Diseases Society of America. <i>Clin Inf Dis</i>. 2006;43(12):1499-1539.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/17109284/pubmed\" target=\"_blank\" id=\"17109284\">17109284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobs MR, Felmingham D, Appelbaum PC, et al, &ldquo;The Alexander Project 1998-2000: Susceptibility of Pathogens Isolated From Community-Acquired Respiratory Tract Infection to Commonly Used Antimicrobial Agents,&rdquo; <i>J Antimicrob Chemother</i>, 2003, 52(2):229-46.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khaliq Y and Zhanel GG, &ldquo;Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,&rdquo; <i>Clin Infect Dis</i>, 2003, 36(11):1404-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/12766835/pubmed\" target=\"_blank\" id=\"12766835\">12766835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lawrence KR, Adra M, and Keir C, &ldquo;Hypoglycemia-Induced Anoxic Brain Injury Possibly Associated With Levofloxacin,&rdquo; <i>J Infect</i>, 2006, 52(6):e177-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16269178/pubmed\" target=\"_blank\" id=\"16269178\">16269178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loebstein R, Addis A, Ho E, et al, &ldquo;Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter, Prospective Controlled Study,&rdquo; <i>Antimicrob Agents Chemother</i>, 1998, 42(6):1336-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/9624471/pubmed\" target=\"_blank\" id=\"9624471\">9624471</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malone RS, Fish DN, Abraham E, et al, &ldquo;Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,&rdquo; <i>Antimicrob Agents Chemother</i>, 2001, 45(10):2949-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/11557500/pubmed\" target=\"_blank\" id=\"11557500\">11557500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23484334\"></a>Manickam P, Nagaraju B, Selvaraj V, et al. Team of Study Investigators. Efficacy of single-dose chemotherapy (rifampicin, ofloxacin and minocycline-ROM) in PB leprosy patients with 2 to 5 skin lesions, India: randomised double-blind trial. <i>Indian J Lepr</i>. 2012;84(3):195-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/23484334/pubmed\" target=\"_blank\" id=\"23484334\">23484334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohr JF, McKinnon PS, Peymann PJ, et al, &ldquo;A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,&rdquo; <i>PharmacBalotherapy</i>, 2005, 25(10):1303-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16185173/pubmed\" target=\"_blank\" id=\"16185173\">16185173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. <i>Gastroenterology</i>. 1996;111(4):1011-1017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/8831596/pubmed\" target=\"_blank\" id=\"8831596\">8831596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nilsson-Ehle I and Ljungberg B, &ldquo;Quinolone Disposition in the Elderly: Practical Implications,&rdquo; <i>Drugs Aging</i>, 1991, 1(4):279-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/1794020/pubmed\" target=\"_blank\" id=\"1794020\">1794020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ofloxacin [prescribing information]. Canton, MS: Larken Laboratories; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4392-4398.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/24841264 /pubmed\" target=\"_blank\" id=\"24841264 \">24841264 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie LY, Juurlink DN, Kopp A, et al, &ldquo;Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults,&rdquo; <i>N Engl J Med</i>, 2006, 354(13):1352-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16510739/pubmed\" target=\"_blank\" id=\"16510739\">16510739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peled Y, Friedman S, Hod M, et al, &ldquo;Ofloxacin During the Second Trimester of Pregnancy,&rdquo; <i>DICP</i>, 1991, 25(11):1181-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/1763532/pubmed\" target=\"_blank\" id=\"1763532\">1763532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections. http://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php. Updated March 1, 2016. Accessed March 7, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol</i>. 2016;111(5):602-622. doi: 10.1038/ajg.2016.126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/27068718/pubmed\" target=\"_blank\" id=\"27068718\">27068718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA; American Association for the Study of Liver Diseases. Practice guideline: management of adult patients with ascites due to cirrhosis: update 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 6, 2015.23463403</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21914093\"></a>Setia MS, Shinde SS, Jerajani HR, et al. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis. <i>Trop Med Int Health</i>. 2011;16(12):1541-1551.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/21914093/pubmed\" target=\"_blank\" id=\"21914093\">21914093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Szarfman A, Chen M, and Blum MD, &ldquo;More on Fluoroquinolone Antibiotics and Tendon Rupture,&rdquo; <i>N Engl J Med</i>, 1995, 332(3):193.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thalhammer F, Kletzmayr J, El Menyawi I, et al, &ldquo;Ofloxacin Clearance During Hemodialysis: A Comparison of Polysulfone and Cellulose Acetate Hemodialyzers,&rdquo; <i>Am J Kidney Dis</i>, 1998, 32(4):642-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/9774127/pubmed\" target=\"_blank\" id=\"9774127\">9774127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i> Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Dept. Health and Human Services. National Hansen's Disease Program: Recommended treatment regimens. <a href=\"http://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html\" target=\"_blank\">http://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14993633\"></a>Villahermosa LG, Fajardo TT Jr, Abalos RM, et al. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. <i>Am J Trop Med Hyg</i>. 2004;70(2):197-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/14993633/pubmed\" target=\"_blank\" id=\"14993633\">14993633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang S and Rizvi AA, &ldquo;Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient,&rdquo; <i>Am J Med Sci</i>, 2006, 331(6):334-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/16775443/pubmed\" target=\"_blank\" id=\"16775443\">16775443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. WHO Expert Committee on Leprosy. <i>World Health Organ Tech Rep Ser</i>. 2012;(968):1-61, 1 p following 61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/22970604/pubmed\" target=\"_blank\" id=\"22970604\">22970604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    WHO Expert Committee on Leprosy. <i>World Health Organ Tech Rep Ser</i>. 1998;874:1-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/9627517/pubmed\" target=\"_blank\" id=\"9627517\">9627517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo; <i>Ann Pharmacother</i>, 2004, 38:1525-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofloxacin-systemic-drug-information/abstract-text/15252190/pubmed\" target=\"_blank\" id=\"15252190\">15252190</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9892 Version 198.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9496286\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9496295\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9498132\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9497845\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9497846\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9497847\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9497848\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9497986\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9496347\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9496293\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9497866\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9496348\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730957\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9497559\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9497548\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9497549\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9497653\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9497654\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9496354\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9496355\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9497547\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15577087\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9497678\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9497680\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9497988\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961995\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9892|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ofloxacin-systemic-patient-drug-information\" class=\"drug drug_patient\">Ofloxacin (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=ofloxacin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Ofloxacin (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}